Sara Zaknoen | Athena Foundation Board Director
Strategic Oncology Drug Development Consultant | Zed Strategic Consulting
Sara is a Clinical Oncology Consultant at Zed Strategic Consulting with proven success leading oncology clinical research through Phases 1, 2, and 3 with 18 years of large pharmaceutical drug development and venture-funded biotech experience. Her entrepreneurial style led to registration of a billion-dollar drug and extended labels on numerous leading products.
Sara Zaknoen is a strategic and tactical leader combining a big picture, people-oriented approach with a deep scientific acumen. She is skilled at the design of clinical development paths for oncology drugs that combine logic and efficiency and maintain maximum ROI. She has deep experience in all aspects of oncology drug development from pre-IND to NDA and launch.
Sara is a consensus-builder, mentor, and coach with exceptional communication skills-delivering ideas and forward-thinking concepts to Key Opinion Leaders in business, the medical community and academia. Zaknoen has held senior executive roles in leading pharmaceutical companies including Schering-Plough, now Merck, and Novartis Oncology as well as serving as CMO for a number of small venture-funded and public companies.
Current clients include San Diego area public and private Biotech companies and large multinational pharmaceutical companies. Working on full clinical development of high priority clinical assets. Tasks include clinical development strategy for multiple indications, management of clinical teams including clinical operations, contributing and editing Clinical Study Reports, Investigator Brochures and IND and NDA documents.
Zaknoen's extensive education includes a Medical Staff Fellow at the National Institutes of Health, NCI/Metabolism Branch and a Fellow in Hematology/Oncology at University of Minnesota, Dept. of Medicine, Div. of Hematology.